Long-term data from the ISCHEMIA-EXTEND trial indicates that routine invasive heart procedures for stable coronary disease provide no survival benefit over medication, impacting the clinical outlook for firms like Boston Scientific, Abbott, and Medtronic.
The ISCHEMIA-EXTEND study (presented Nov 7, 2026) found nearly identical death rates after nearly a decade — 26 percent for early invasive care versus 27 percent for drugs-only — reinforcing that stents do not extend survival in stable coronary disease. This weighs on demand arguments for routine stenting, a key interventional cardiology business. The finding builds on already-published ISCHEMIA results, so much of the negative signal is likely priced in.
The study supports stents for relieving chest pain and improving quality of life, but says they are unlikely to help stable patients live longer, which could favor more conservative drug-first treatment in stable disease.
The ISCHEMIA-EXTEND follow-up showed death rates of 26 percent versus 27 percent between early stent/bypass care and drugs-only care in over 5,000 stable coronary disease patients, arguing against routine early procedures for survival. Broad negative read-across for the stent market touches Abbott's cardiovascular device business. The article names no company, and the result confirms prior ISCHEMIA evidence, limiting the surprise.
It extends prior ISCHEMIA trial findings, showing that after nearly a decade survival was essentially the same (26 percent vs 27 percent) whether patients had early procedures or drugs first.
The new ISCHEMIA-EXTEND data presented on November 7 confirm that early invasive procedures do not reduce death rates (26 percent vs 27 percent) in stable coronary artery disease, a modest headwind for the interventional cardiology device market. No specific company is named in the article and the result largely confirms a decade-old trial, so the practical market effect is likely small.
The study tracked whether 96 percent of participants were alive or had died and recorded 1,071 deaths up to 13 years after patients entered the study.
The ISCHEMIA-EXTEND study, presented at the American Heart Association sessions, confirms that early invasive procedures like stents do not offer a survival advantage over drug therapy for stable coronary disease. After nearly a decade, death rates were 26 percent for invasive care versus 27 percent for conservative treatment, reinforcing that procedures should primarily focus on symptom relief rather than mortality reduction.
No, the study confirms that stents and bypass surgeries are effective for relieving chest pain and improving quality of life, and remain lifesaving for patients experiencing active heart attacks.
The findings represent a modest headwind for companies like Boston Scientific, Abbott, and Medtronic, as they support a more conservative, drug-first approach for stable patients rather than routine early intervention.